MOXIFLOXACIN APO (Accelagen Pty Ltd)
Product name
MOXIFLOXACIN APO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 working days (255)
Active ingredients
moxifloxacin (as hydrochloride)
Registration type
New generic medicine
Indication
MOXIFLOXACIN APO (tablets) are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions:
- Acute bacterial sinusitis
- Community acquired pneumonia
- Acute exacerbations of chronic bronchitis
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with MOXIFLOXACIN APO may be initiated, in some conditions, before results of these tests are known. Once results become available, therapy should be continued with the most appropriate antibiotic therapy.
Consideration should be given to available official guidance on the appropriate use of antibacterial agents.